Other aws Support

Other support for Life Science start-ups

With the aws Venture Capital Initiative we want to stimulate the financing of research- and technology-oriented start-ups and win international venture capital funds for an increased engagement in Austria. Investments in VC funds, which have a focus on investments in technology-oriented Austrian start-ups - at market conditions.

https://www.aws.at/aws-venture-capital-initiative/

 

With aws Business Angel Fund, we help start-ups to take off by doubling the equity holdings of business angels through co-investments.

https://www.aws.at/aws-business-angel-fonds/

 

With aws protecting innovation, we support you in developing your individual, business-specific intellectual property strategy, i.e. we help identify, secure, protect, and exploit your intellectual property.

https://www.aws.at/en/aws-protecting-innovation/

 

 

Wings4innovation GmbH

wings4innovation GmbH (w4i) was founded as affiliate of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), a new European financing vehicle for early-stage drug discovery projects with focus in Austria and Germany to facilitate translation of promising results from Austrian basic research organisations in life sciences into professional drug discovery projects and their commercialisation w4i has access to funds of KHAN-I and is open to all research organisations in Austria.

More information at: https://www.w4i.org/index.html

 

News

Icon LISA News = LISA News
24.01.2022
Fasten gegen Krebs: Forscher*innen der Med Uni Graz untersuchen Wege zur Bekämpfung des Leberkarzinoms
24.01.2022
Big Data - von der Forschung zu Lösungen für den onkologischen Alltag von Patientinnen und Patienten
24.01.2022
Cyprumed GmbH Enters Agreement with Ferring Pharmaceuticals for Development of Oral Drug Delivery Technology for Patient-Centric non-invasive Peptide Therapeutics
21.01.2022
Nationalrat schafft einheitliche Rahmenbedingungen für klinische Prüfungen von Humanarzneimitteln
21.01.2022
Marinomed announces the appointment of Dr. Cornelia Kutzer as Chief Business Officer